Shilpa Rele, MHA

  • 2Articles
  • 9.6KReads
  • 2013–2015Active
  • 11Collaborators
  • 6Citations

About

Shilpa Rele, MHA, has published research on major depressive disorder and fibromyalgia, focusing on pharmacological interventions and their effects on cognition, pain, and fatigue. Contributions include clinical trials evaluating vilazodone dose-initiation strategies following antidepressant switches and the impact of milnacipran on neurocognitive and somatic symptoms. Rele's work spans neurology and psychiatry, with articles appearing between 2013 and 2015 in Psychiatrist.com journals.

Publications

PCC
Article

An 8-Week Randomized, Double-Blind Trial Comparing Efficacy, Safety, and Tolerability of 3 Vilazodone Dose-Initiation Strategies Following Switch From SSRIs and SNRIs in Major Depressive Disorder

August 6, 2015

Do patients clinically benefit from a switch from initial antidepressant treatment to vilazodone? How often do they experience adverse events? To answer these questions, the authors of this study...
, , , et al
PCC
Article

Effects of Milnacipran on Neurocognition, Pain, and Fatigue in Fibromyalgia: A 13-Week, Randomized, Placebo-Controlled, Crossover Trial

December 26, 2013

Is milnacipran a safe and effective treatment for improving cognitive function in fibromyalgia? See these study results to find out.
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe